Austedo is not an antipsychotic. It belongs to a completely different drug class called VMAT2 inhibitors (vesicular monoamine transporter 2 inhibitors). The confusion is understandable, though, because Austedo is often prescribed to treat a movement disorder that antipsychotics themselves cause. Here’s how the two differ and why the distinction matters for your health.
How Austedo Actually Works
Austedo (deutetrabenazine) reduces involuntary movements by lowering the amount of dopamine available in the brain, but it does this through a fundamentally different mechanism than antipsychotics. VMAT2 inhibitors work on the supply side: they block a transporter protein that loads dopamine into tiny storage compartments inside nerve cells. With less dopamine packaged and ready for release, the signals that trigger abnormal movements get quieter.
Antipsychotics take the opposite approach. They work on the receiving end by blocking dopamine receptors on the surface of brain cells after dopamine has already been released. This receptor-blocking action is what makes antipsychotics effective for conditions like schizophrenia, but it’s also what creates problems. When receptors are chronically blocked, they can become hypersensitive, which is one reason long-term antipsychotic use sometimes leads to the very movement disorders Austedo is designed to treat.
The FDA approved Austedo in 2017 for two conditions: tardive dyskinesia in adults and chorea (involuntary jerking movements) associated with Huntington’s disease. Neither of these is a psychiatric condition in the way schizophrenia or bipolar disorder are, which further underscores that Austedo fills a very different role than antipsychotics.
Why the Two Get Confused
The link between Austedo and antipsychotics is tight in practice, even though they’re pharmacologically distinct. Tardive dyskinesia, one of the primary conditions Austedo treats, is caused by medications that block dopamine receptors. Antipsychotics are the most common culprit. More than 20% of people who take antipsychotics continuously for longer than three months develop tardive dyskinesia, and the risk climbs with age: 25% to 30% of older adults on these medications begin showing signs each year.
So Austedo often enters the picture specifically because an antipsychotic created a problem. In the clinical trials that led to its approval for tardive dyskinesia, 71% of participants were taking atypical antipsychotics and another 14% were on typical antipsychotics at the same time. Austedo was added on top of those medications, not used as a replacement. This co-prescribing pattern is common in real-world practice too, which may contribute to the impression that Austedo is somehow in the same family.
Taking Austedo Alongside Antipsychotics
Because most people prescribed Austedo for tardive dyskinesia are already on an antipsychotic, the combination is well-studied. But it does carry specific risks worth knowing about. Using the two together can increase the chance of parkinsonian symptoms (stiffness, slowness, tremor), a dangerous condition called neuroleptic malignant syndrome, and akathisia, which is a distressing feeling of inner restlessness that makes it hard to sit still.
There’s also a heart rhythm concern. Both Austedo and certain antipsychotics can prolong a specific interval in the heart’s electrical cycle called QTc. Combining them may amplify that effect, so doctors typically monitor heart rhythm more closely. Sedation is another additive risk. If you’re taking an antipsychotic that makes you drowsy, adding Austedo can deepen that effect.
Other VMAT2 Inhibitors
Austedo isn’t the only drug in its class. Ingrezza (valbenazine) is another VMAT2 inhibitor approved for tardive dyskinesia, and Xenazine (tetrabenazine) is an older version approved for Huntington’s chorea. Austedo is actually a modified form of tetrabenazine, chemically altered to last longer in the body. This means it can be taken twice daily instead of three times, and its effects tend to be more stable throughout the day.
Ingrezza has the simplest dosing of the three, taken just once daily. Xenazine requires dosing three times a day and has the widest dose range, which can make finding the right dose more involved. None of these medications are antipsychotics. They all share the same core mechanism of reducing monoamine storage in nerve terminals rather than blocking receptors.
Key Safety Considerations
Austedo carries a boxed warning related to depression and suicidal thoughts, particularly in people with Huntington’s disease. The drug depletes not just dopamine but also serotonin, norepinephrine, and histamine from nerve terminals. That broad effect on brain chemistry means mood changes are a real concern, especially in populations already at elevated risk for depression.
The medication is started at a low dose and increased gradually, in weekly increments, until symptoms improve or side effects limit further increases. For tardive dyskinesia, the maximum dose is 48 mg per day, split into two doses. This slow titration helps minimize side effects but also means it can take several weeks before you and your doctor know whether the medication is working well enough.